stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Current ratio
Oruka Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 38.5×, up 16.1× from fiscal 2025 (22.4×). Over the past ten years it has ranged from 5.9× (fiscal 2017) to 59.0× (fiscal 2023); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 22.4× | (22.59%) |
| FY2024 | 28.9× | (51.04%) |
| FY2023 | 59.0× | 56.45% |
| FY2022 | 37.7× | 142.45% |
| FY2021 | 15.6× | 8.94% |
| FY2020 | 14.3× | 55.94% |
| FY2019 | 9.2× | 7.16% |
| FY2018 | 8.5× | 43.84% |
| FY2017 | 5.9× | (33.62%) |
| FY2016 | 9.0× | (65.41%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 38.5× | 62.07% |
| Mar 2026 | 23.8× | 6.25% |
| Dec 2025 | 22.4× | 32.04% |
| Sep 2025 | 16.9× | (38.22%) |
| 42 more quarters | Free account |
Against its own ten years
Low 5.9×
High 59.0×
Ten-year median
15.6×
Current reading's percentile
64
Current ratio against peers
| Company | Current ratio |
|---|---|
| ORKA Oruka Therapeutics, Inc. | 38.5× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 33.6× |
| CGON CG Oncology, Inc. compare | 22.2× |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.9× |
| IMVT Immunovant, Inc. compare | 7.3× |
| KOD Kodiak Sciences Inc. compare | 2.5× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 2.1× |
| AXSM Axsome Therapeutics, Inc. compare | 1.4× |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.2× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)